Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.
Saved in:
| Title: | Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer. |
|---|---|
| Authors: | Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Paolo_Tarantino@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Paolo_Tarantino@dfci.harvard.edu.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Paolo_Tarantino@dfci.harvard.edu., Kim SE; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Hughes ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Yale School of Medicine, New Haven, CT, USA., Kusmick RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Smith K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Brasó-Maristany F; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Reveal Genomics, Barcelona, Spain., Nyein Chan NN; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA., Paré Brunet L; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Alder L; Duke Cancer Institute, Durham, NC, USA., Garcia-Cortes D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Boston, MA, USA., Gomez Tejeda Zanudo J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Boston, MA, USA., Pereslete AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Noteware L; Duke Cancer Institute, Durham, NC, USA., Moore H; Duke Cancer Institute, Durham, NC, USA., Van Swearingen AED; Duke Cancer Institute, Durham, NC, USA., Li T; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Gupta H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., D'Amico O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Martini A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Morganti S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Boston, MA, USA., Spindel J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cook C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., McLaughlin C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dvir K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garrido-Castro AC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sammons S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Files J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sendrick K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Buck S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dillon D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jeselsohn R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Li YY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Boston, MA, USA., Cherniack AD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Boston, MA, USA., LoRusso P; Yale School of Medicine, New Haven, CT, USA., Lustberg M; Yale School of Medicine, New Haven, CT, USA., Vega-León R; Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Reveal Genomics, Barcelona, Spain., Pardo F; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Reveal Genomics, Barcelona, Spain., Davis J; Ignite Proteomics, Golden, CO, USA., Mueller C; Ignite Proteomics, Golden, CO, USA., Corgiat B; Ignite Proteomics, Golden, CO, USA., Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; European Institute of Oncology IRCCS, Milan, Italy., Anders CK; Duke Cancer Institute, Durham, NC, USA., Petricoin EF; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA., Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA., Prat A; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Reveal Genomics, Barcelona, Spain.; Clínic Barcelona Comprehensive Cancer Center, Barcelona, Spain., Tayob N; Harvard Medical School, Boston, MA, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Sara_Tolaney@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Sara_Tolaney@dfci.harvard.edu. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2026 Mar 13; Vol. 10 (1). Date of Electronic Publication: 2026 Mar 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2397-768X |
|---|---|
| DOI: | 10.1038/s41698-026-01365-6 |
